Микробы хорошие и плохие. Наше здоровье и выживание в мире бактерий

24 Karina Xavier, Bonnie Bassler, “Interference with AI-2-Mediated Bacterial Cell-Cell Communication”, Nature 437 (2005), 750–753.

25 E. Barth et al., “In Vitro and In Vivo Comparative Colonization of Staphylococcus aureus and Staphylococcus epidermidis on Orthopaedic Implant Materials”, Biomaterials 10 (1989), 325–328.

26 Andrea Giacometti et al., “RNA III Inhibiting Peptide Inhibits In Vivo Biofilm Formation by Drug-Resistant Staphylococcus aureus”, Antimicrobial Agents and Chemotherapy 47 (2003), 1979–1983.

27 Garth Ehrlich et al., “Engineering Approaches for the Detection and Control of Orthopaedic Biofilm Infections”, Clinical Orthopaedics and Related Research 437 (2005), 59–66.

28 Philip Stewart, Ross Carlson, “Anti-biofilm Properties of Chitosan-Coated Surfaces”, 232nd national meeting of the American Chemical Society, poster presentation COLL 021, September 10, 2006.

29 Anneta Razatos et al., “Force Measurements Between Bacteria and Polyethylene Glycol Coated Surfaces”, Langmuir 16 (2000), 9155–9158; David Adam, “Bacteria Get the Brush Off", www.nature.com / n ews / 2000 / 001219 / full / news001221-6.html.

30 MedImmune, 2005 Annual Report, Gaithersburg, MD.

31 A. P. Simopoulos, “Omega-3 Fatty Acids in Inflammation and Autoimmune Diseases”, Journal of the American College of Nutrition 21 (2002), 495–505; F. Holguin et al., “Cardiac Autonomic Changes Associated with Fish Oil vs Soy Oi Supplmentation in the Elderly”, Chest 127 (2005), 1102–1107; A. A. Berbert et al., “Supplementation of Fish Oil and Olive Oil in Patients with Rheumatoid Arthritis”, Nutrition 21 (2005), 131–136.

32 Misha Luyer et al., “Nutritional Stimulation of Cholecystokinin Receptors Inhibits Inflammation via the Vagus Nerve”, Journal of Experimental Medicine 202 (2005), 1023–1029.

33 T. Chen et al., “Mononuclear Cell Response to Enterobacteria and Gram-positive Cell Walls of Normal Intestinal Microbiota in Early Rheumatoid Arthritis and Other Inflammatory Arthritides”, Clinical and Experimental Rheumatology 20 (2002), 193–200; Erika Isolauri,

“Probiotics in Human Disease”, American Journal of Clinical Nutrition 73 (2001), 1142S – 1146S; Kent Erickson and Neil Hubbard, “Probiotic Immunomodulation in Health and Disease”, Journal of Nutrition 130 (2000X403S – 409S.

34 K. Hatakka et al., “Effects of Probiotic Therapy on the Activity and Activation of Mild Rheumatoid Arthritis – A Pilot Study”, Scandinavian Journal of Rheumatology 32 (2003), 211–215; Ehud Baharav et al., “Lactobacillus GG Bacteria Ameliorate Arthritis in Lewis Rats”, Journal of Nutrition 134 (2004), 1964–1969; T. M. Chapman et al., “VSL#3 Probiotic Mixture: A Review of Its Use in Chronic Inflammatory Bowel Diseases”, Drugs 66 (2006), 13711387; O. Karimi et al., “Probiotics (VSL#3) in Arthralgia in Patients with Ulcerative Colitis and Crohn’s Disease: A Pilot Study”, Drugs Today 41 (2005), 453–459; Philippe Marteau et al., “Protection from Gastrointestinal Diseases with the Use of Probiotics”, American Journal of Clinical Nutrition 73 (2001), 430S – 436S.

35 Henri Braat et al., “A Phase 1 Trial with Transgenic Bacteria Expressing Interleukin-10 in Crohn’s Disease”, Clinical Gastroenterology and Hepatology 4 (2006), 754–759.

36 M. Kalliomaki et al., “Probiotics in Primary Prevention of Atopic Disease: A Randomised Placebo-Controlled Trial”, Lancet 357 (2001), 1076–1079; M. Kalliomaki et al., “Probiotics and Prevention of Atopic

Disease: 4-year Follow-up of a Randomised Placebo-Controlled Trial”, Lancet 361 (2003), 1869–1871.

37 M. Viljanen, “Probiotics in the Treatment of Atopic Eczema/Dermatitis Syndrome in Infants: A Double-Blind Placebo-Controlled Trial”, Allergy 60 (2005), 494–500.